Laura J Johnston, MD
Hematopoietic Cell Transplantation and Cellular Therapy · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Johnston’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G70540 · Current
Licensed to practise in California · since 1990 · expires 2028-07-31 · University of Minnesota Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$61,869
Medicare paid this office $61,869 for 102 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $31,992 | $106 |
| Long return visit (40+ min) | 52 | $20,854 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,412 | $155 |
| Hospital discharge day management, more than 30 minutes | 25 | $2,639 | $101 |
| Long return visit (40+ min) | 13 | $1,509 | $94 |
Who their Medicare patients are
102 Original Medicare patients in 2024. Average age 67 · Under 65 21% · 85 and older 0% · Women 44% · Also on Medicaid 33% · Health risk score 3.25. Above the middle of the specialty; the typical hematopoietic cell transplantation and cellular therapy clinician is at 2.85.
Conditions among them: High blood pressure 68% · Chronic kidney disease 27% · Diabetes 26% · Atrial fibrillation 22% · Coronary heart disease 19% · Depression 19% · COPD 16% · Heart failure 14% · Cancer 14% · Dementia 11%.
The office billed $211,221, Medicare allowed $79,244 and paid $61,869; for 544 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 102 | 544 | 67 | 3.25 | $211,221 | $61,869 |
| 2023 | 81 | 338 | 68 | 3.19 | $117,462 | $40,637 |
| 2022 | 90 | 361 | 66 | 2.82 | $140,933 | $39,062 |
| 2021 | 114 | 427 | 66 | 3.10 | $156,012 | $47,612 |
| 2020 | 88 | 421 | 66 | 3.58 | $175,801 | $44,017 |
| 2019 | 81 | 376 | 64 | 3.28 | $169,457 | $36,156 |
| 2018 | 86 | 409 | 65 | 3.39 | $179,528 | $37,016 |
| 2017 | 96 | 445 | 65 | 3.37 | $176,731 | $37,482 |
| 2016 | 76 | 283 | 63 | 3.22 | $111,958 | $25,799 |
| 2015 | 67 | 292 | 64 | 3.41 | $107,437 | $24,710 |
| 2014 | 93 | 381 | 60 | 3.10 | $150,976 | $31,059 |
| 2013 | 75 | 389 | 61 | 2.84 | $144,406 | $34,022 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 51 | $20,012 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $15,577 | $110 |
2022: 3 services
| Long return visit (40+ min) | 67 | $17,525 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $14,844 | $93 |
| Return visit (30+ min) | 16 | $1,448 | $85 |
2021: 3 services
| Long return visit (40+ min) | 76 | $26,709 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $13,173 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $3,083 | $181 |
2020: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $20,153 | $97 |
| Long return visit (40+ min) | 45 | $12,688 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $5,095 | $189 |
| Long return visit (40+ min) | 16 | $1,978 | $94 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,934 | $102 |
2019: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $13,867 | $94 |
| Long return visit (40+ min) | 39 | $12,407 | $96 |
| Return visit (30+ min) | 27 | $3,892 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,753 | $184 |
2018: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $14,555 | $93 |
| Long return visit (40+ min) | 32 | $9,296 | $95 |
| Return visit (30+ min) | 37 | $7,837 | $69 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,365 | $182 |
2017: 4 services
| Return visit (30+ min) | 50 | $15,131 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $10,470 | $93 |
| Long return visit (40+ min) | 29 | $6,660 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,357 | $181 |
2016: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $11,389 | $93 |
| Long return visit (40+ min) | 27 | $6,399 | $93 |
| Return visit (30+ min) | 24 | $3,515 | $68 |
2015: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $10,240 | $92 |
| Long return visit (40+ min) | 26 | $5,996 | $83 |
| Return visit (30+ min) | 27 | $4,764 | $64 |
2014: 3 services
| Return visit (30+ min) | 51 | $13,084 | $67 |
| Long return visit (40+ min) | 32 | $8,814 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,875 | $89 |
2013: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $16,547 | $90 |
| Long return visit (40+ min) | 28 | $7,001 | $90 |
| Return visit (30+ min) | 28 | $5,296 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,104 | $175 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,237 | $95 |
Medicaid work
$21,508 in 2024
Medicaid paid $21,508 for 192 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 127 | $17,204 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 65 | $4,303 |
| 2024 | 192 | 2 | 17 | $21,508 |
| 2023 | 221 | 1 | 26 | $12,856 |
| 2022 | 208 | 2 | 34 | $13,681 |
| 2021 | 178 | 1 | 24 | $11,703 |
| 2020 | 51 | 1 | 16 | $3,128 |
| 2019 | 40 | 1 | 13 | $5,406 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 221 | $12,856 |
2022
| Long return visit (40+ min) | 176 | $11,817 |
| Return visit (30+ min) | 32 | $1,864 |
2021
| Long return visit (40+ min) | 178 | $11,703 |
2020
| Long return visit (40+ min) | 51 | $3,128 |
2019
| Return visit (30+ min) | 40 | $5,406 |
Drugs they prescribed that Part D paid
$1,099,460
Pharmacies billed $1,099,460 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 230) in 2024. At or below the middle of the specialty; the typical hematopoietic cell transplantation and cellular therapy clinician is at 3%.
160 generic and 70 brand-name prescriptions · $1,099,460 in drug cost · 28 antibiotic prescriptions to 16 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jakafi | 34 | $557,494 | $16,397 |
| Rezurock | 16 | $505,735 | $31,608 |
| Acyclovir | 36 | $1,703 | $47 |
| Gabapentin | 12 | $245 | $20 |
| Sulfamethoxazole-Trimethoprim | 16 | $92 | $6 |
Year by year
| 2024 | 230 | 40 | 0% (0) | 30% | $1,099,460 |
| 2023 | 208 | 30 | None | 20% | $619,726 |
| 2022 | 300 | 42 | 0% (0) | 22% | $966,458 |
| 2021 | 477 | 48 | 0% (0) | 18% | $987,002 |
| 2020 | 351 | 35 | 0% (0) | 9% | $302,551 |
| 2019 | 556 | 39 | None | 10% | $345,181 |
| 2018 | 562 | 51 | None | None | $259,265 |
| 2017 | 523 | 44 | 5% (27) | 7% | $113,389 |
| 2016 | 584 | 50 | 3% (18) | None | $148,208 |
| 2015 | 514 | 44 | 4% (19) | None | $97,699 |
| 2014 | 627 | 58 | 4% (24) | None | $172,768 |
| 2013 | 457 | 54 | 7% (30) | None | $202,998 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Jakafi | 25 | $514,542 | $20,582 |
| Posaconazole | 15 | $52,434 | $3,496 |
| Acyclovir | 38 | $1,441 | $38 |
| Gabapentin | 11 | $367 | $33 |
| Sulfamethoxazole-Trimethoprim | 24 | $247 | $10 |
2022: 5 drugs
| Jakafi | 39 | $708,819 | $18,175 |
| Posaconazole | 25 | $57,998 | $2,320 |
| Sirolimus | 11 | $7,879 | $716 |
| Acyclovir | 68 | $2,753 | $40 |
| Sulfamethoxazole-Trimethoprim | 33 | $234 | $7 |
2021: 14 drugs
| Jakafi | 48 | $717,160 | $14,941 |
| Posaconazole | 29 | $74,688 | $2,575 |
| Zarxio | 17 | $65,760 | $3,868 |
| Atovaquone | 30 | $23,312 | $777 |
| Sirolimus | 18 | $10,430 | $579 |
| Acyclovir | 90 | $3,813 | $42 |
| Ursodiol | 14 | $1,652 | $118 |
| Dexamethasone | 15 | $831 | $55 |
| Sulfamethoxazole-Trimethoprim | 61 | $566 | $9 |
| Prochlorperazine Maleate | 14 | $272 | $19 |
| Ondansetron | 22 | $232 | $11 |
| Levofloxacin | 14 | $194 | $14 |
| Pantoprazole | 15 | $188 | $13 |
| Amoxicillin | 16 | $57 | $4 |
2020: 10 drugs
| Jakafi | 12 | $203,566 | $16,964 |
| Atovaquone | 13 | $8,234 | $633 |
| Acyclovir | 64 | $1,982 | $31 |
| Tacrolimus | 24 | $1,838 | $77 |
| Mycophenolate Mofetil | 11 | $1,522 | $138 |
| Dexamethasone | 13 | $795 | $61 |
| Sulfamethoxazole-Trimethoprim | 43 | $594 | $14 |
| Gabapentin | 15 | $308 | $21 |
| Prednisone | 16 | $193 | $12 |
| Pantoprazole | 15 | $102 | $7 |
2019: 14 drugs
| Jakafi | 12 | $174,764 | $14,564 |
| Sirolimus | 30 | $22,662 | $755 |
| Entecavir | 17 | $5,266 | $310 |
| Tacrolimus | 31 | $3,113 | $100 |
| Acyclovir | 102 | $2,354 | $23 |
| Mycophenolate Mofetil | 17 | $1,095 | $64 |
| Sulfamethoxazole-Trimethoprim | 67 | $745 | $11 |
| Prednisone | 35 | $539 | $15 |
| Gabapentin | 12 | $382 | $32 |
| Famotidine | 24 | $242 | $10 |
| Pantoprazole | 14 | $204 | $15 |
| Ondansetron | 12 | $169 | $14 |
| Ranitidine | 12 | $130 | $11 |
| Lorazepam | 12 | $77 | $6 |
2018: 18 drugs
| Zarxio | None | 12 | $98,603 | $8,217 |
| Gamunex-C | Immune globulin | 22 | $37,983 | $1,727 |
| Sirolimus | None | 24 | $11,130 | $464 |
| Atovaquone | None | 14 | $6,316 | $451 |
| Acyclovir | None | 69 | $1,382 | $20 |
| Tacrolimus | None | 13 | $1,181 | $91 |
| Prednisone | None | 51 | $597 | $12 |
| Ondansetron | None | 29 | $413 | $14 |
| Sulfamethoxazole-Trimethoprim | None | 37 | $402 | $11 |
| Levofloxacin | None | 11 | $317 | $29 |
| Famotidine | None | 21 | $263 | $13 |
| Pantoprazole | None | 19 | $207 | $11 |
| Ranitidine | None | 15 | $152 | $10 |
| Prochlorperazine Maleate | None | 15 | $137 | $9 |
| Ciprofloxacin | None | 12 | $124 | $10 |
| Lorazepam | None | 17 | $105 | $6 |
| Omeprazole | None | 13 | $89 | $7 |
| Amlodipine Besylate | None | 11 | $67 | $6 |
2017: 17 drugs
| Sirolimus | 11 | $4,298 | $391 |
| Tacrolimus | 12 | $1,380 | $115 |
| Mycophenolate Mofetil | 22 | $828 | $38 |
| Acyclovir | 57 | $789 | $14 |
| Hydrocortisone | 11 | $732 | $67 |
| Sulfamethoxazole-Trimethoprim | 32 | $326 | $10 |
| Gabapentin | 19 | $285 | $15 |
| Ondansetron | 20 | $238 | $12 |
| Ciprofloxacin | 17 | $223 | $13 |
| Prednisone | 28 | $206 | $7 |
| Pantoprazole | 21 | $118 | $6 |
| Lorazepam | 14 | $98 | $7 |
| Ranitidine | 11 | $92 | $8 |
| Prochlorperazine Maleate | 11 | $83 | $8 |
| Metoprolol | 12 | $78 | $7 |
| Azithromycin | 12 | $71 | $6 |
| Amlodipine Besylate | 14 | $57 | $4 |
2016: 16 drugs
| Gamunex-C | Immune globulin | 20 | $27,561 | $1,378 |
| Acyclovir | None | 91 | $1,731 | $19 |
| Tacrolimus | None | 14 | $911 | $65 |
| Sulfamethoxazole-Trimethoprim | None | 51 | $420 | $8 |
| Ciprofloxacin | None | 19 | $294 | $15 |
| Azithromycin | None | 17 | $293 | $17 |
| Prednisone | None | 25 | $286 | $11 |
| Montelukast | None | 12 | $248 | $21 |
| Gabapentin | None | 15 | $238 | $16 |
| Omeprazole | None | 17 | $129 | $8 |
| Prochlorperazine Maleate | None | 14 | $126 | $9 |
| Amlodipine Besylate | None | 25 | $96 | $4 |
| Pantoprazole | None | 18 | $91 | $5 |
| Lorazepam | None | 11 | $84 | $8 |
| Lovastatin | None | 11 | $72 | $7 |
| Fluocinonide | None | 14 | $59 | $4 |
2015: 13 drugs
| Acyclovir | 75 | $1,827 | $24 |
| Tacrolimus | 20 | $1,604 | $80 |
| Azithromycin | 21 | $805 | $38 |
| Gabapentin | 22 | $470 | $21 |
| Hydrocodone-Acetaminophen | 11 | $447 | $41 |
| Sulfamethoxazole-Trimethoprim | 50 | $433 | $9 |
| Potassium Chloride | 20 | $312 | $16 |
| Prednisone | 23 | $215 | $9 |
| Omeprazole | 16 | $213 | $13 |
| Montelukast | 22 | $187 | $9 |
| Ciprofloxacin | 13 | $181 | $14 |
| Ranitidine | 12 | $109 | $9 |
| Lorazepam | 12 | $78 | $7 |
2014: 16 drugs
| Voriconazole | 21 | $51,093 | $2,433 |
| Cyclosporine Modified | 19 | $5,237 | $276 |
| Acyclovir | 99 | $2,422 | $24 |
| Tacrolimus | 12 | $1,143 | $95 |
| Sulfamethoxazole-Trimethoprim | 60 | $793 | $13 |
| Azithromycin | 33 | $713 | $22 |
| Prednisone | 45 | $626 | $14 |
| Montelukast | 31 | $535 | $17 |
| Gabapentin | 13 | $416 | $32 |
| Omeprazole | 22 | $386 | $18 |
| Hydrocodone-Acetaminophen | 12 | $260 | $22 |
| Potassium Chloride | 11 | $185 | $17 |
| Levofloxacin | 13 | $182 | $14 |
| Ciprofloxacin | 12 | $118 | $10 |
| Amlodipine Besylate | 14 | $106 | $8 |
| Ranitidine | 11 | $100 | $9 |
2013: 9 drugs
| Voriconazole | 28 | $57,210 | $2,043 |
| Mepron | 17 | $15,476 | $910 |
| Tacrolimus | 15 | $1,950 | $130 |
| Acyclovir | 50 | $1,671 | $33 |
| Azithromycin | 17 | $749 | $44 |
| Sulfamethoxazole-Trimethoprim | 34 | $506 | $15 |
| Hydrocodone-Acetaminophen | 15 | $376 | $25 |
| Prednisone | 32 | $308 | $10 |
| Omeprazole | 13 | $307 | $24 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| National Marrow Donor Program · Composite Health Assessment Risk Model (Charm) for Older Adults · 2022 | Their institution | $1,177 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1649327016
- Licence
- CA G70540California G70540: Current · expires 2028-07-31
- Trained
- University of Minnesota Medical School, 1989
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-01-05
- NPI last updated
- 2024-04-25
- NPI record certified
- 2024-04-25
This is when the NPI record was last certified, not a medical board exam.